Skip to main content
. Author manuscript; available in PMC: 2021 May 31.
Published in final edited form as: Clin Cancer Res. 2020 Jun 12;26(19):5120–5128. doi: 10.1158/1078-0432.CCR-19-4162

Table 2.

Comparison of clinical variables between all treated patients and TMB-evaluable patients

Characteristic All treated patients
N = 270
TMB-evaluable patients
n = 139

Mean age (range), years 65.0 (38–90) 64.5 (38–85)

Age group, %
 <65 years 45.2 45.3
 ≥65 and <75 years 40.7 42.4
 ≥75 years 14.1 12.2

Sex, %
 Male 78.1 78.4
 Female 21.9 21.6

Baseline hemoglobin (g/dL), %
 <10 17.8 18.0
 ≥10 82.2 82.0

Liver metastases, %
 Yes 28.9 33.1
 No 70.4 66.9
 Not reported 0.7

Visceral metastases, %
 Yes 82.6 80.6
 No 16.7 19.4
 Not reported 0.7

Lymph node–only metastases, %
 Yes 16.7 19.4
 No 82.6 80.6
 Not reported 0.7

PD-L1 expression, %
 <1% 54.1 49.6
 ≥1% 45.9 50.4

TMB classification by tertiles, %
 High 33.8
 Medium 33.1
 Low 33.1